|
1) Yano K, Tamada Y, Yatsuhashi H, et al. Dynamic epidemiology of acute viral hepatitis in Japan. Intervirology. 2010; 53: 70-5
|
|
|
|
2) 八橋 弘. 本邦におけるウイルス性急性肝炎の発生状況と治療法に関する研究. 国立病院機構共同臨床研究. 2010. p.1-9
|
|
|
|
|
|
3) Kobayashi M, Ikeda K, Arase Y, et al. Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol. 2008; 80: 1880-4
|
|
|
|
|
|
4) Matsuura K, Tanaka Y, Hige S, et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol. 2009; 47: 1476-83
|
|
|
|
|
|
5) Yoshikawa A, Gotanda Y, Suzuki Y, et al. Age- and gender-specific distributions of hepatitis B virus (HBV) genotypes in Japanese HBV-positive blood donors. Transfusion. 2009; 49: 1314-20
|
|
|
|
|
|
6) Jochum C, Gieseler RK, Gawlista I, et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009; 80: 235-40
|
|
|
|
|
|
7) Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med. 2008; 47: 1293-9
|
|
|
|
|
8) Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010; 55: 775-83
|
|
|
|
|
|
9) Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006; 131: 59-68
|
|
|
|
|
|
10) Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009; 27: 605-11
|
|
|
|
|
|
11) 坪内博仁, 熊田博光, 清澤研道, 他. 免疫抑制・化学療法により発症するB型肝炎対策-厚労省｢難治性の肝・胆道疾患に関する調査研究｣班劇症肝炎分科会および｢肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究｣班合同報告-. 肝臓. 2009; 50: 38-42
|
|
|
|
|
|
12) Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008; 38: 208-17
|
|
|
|
|
|
13) Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007; 13: 508-9
|
|
|
|
|
|
14) Matsumoto T, Marusawa H, Dogaki M, et al. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int. 2010; 30: 1241-2
|
|
|
|
|
|
15) Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008; 28: 718-20
|
|
|
|
|
|
16) Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford). 2009; 48: 448-50
|
|
|
|
|
|
17) Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009; 36: 1188-94
|
|
|
|
|
|
18) Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of inflixi-mab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2010; 67: 189-94
|
|
|
|
|